Medical application of glycyrrhizin chalcone b derivative CTG12 in preparation of nlrp3 inflammasome inhibitor

By modifying the structure of glycyrrhizin B, the compound CTG12 was synthesized, which solved the problems of insufficient safety and specificity of existing NLRP3 inflammasome inhibitors, and achieved highly efficient inhibition of the NLRP3 inflammasome, which can be applied to the treatment of various inflammatory diseases.

CN121081437BActive Publication Date: 2026-07-21CAPITAL UNIVERSITY OF MEDICAL SCIENCES +1
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Filing Date
2025-09-29
Publication Date
2026-07-21

AI Technical Summary

Technical Problem

Existing NLRP3 inflammasome inhibitors have safety issues in clinical applications and lack specificity and efficacy, making it difficult to effectively inhibit the abnormal activation of the NLRP3 inflammasome, which leads to the occurrence of various major human diseases.

Method used

By structurally modifying glycyrrhizin B, the glycyrrhizin B derivative CTG12 was synthesized and designed as a more effective NLRP3 inflammasome inhibitor for the prevention or treatment of diseases associated with abnormal activation of the NLRP3 inflammasome.

Benefits of technology

CTG12 significantly reduced the IC50 value and improved the inhibitory effect on the NLRP3 inflammasome. It has broad spectrum and specificity, and can effectively inhibit the activation of the NLRP3 inflammasome. It can be used to treat a variety of inflammatory diseases, including gout, neurodegenerative diseases, infectious inflammatory diseases, neurological diseases, type 2 diabetes, atherosclerosis and non-alcoholic hepatitis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121081437B_ABST
    Figure CN121081437B_ABST
Patent Text Reader

Abstract

The application provides medical application of glycyrrhizin chalcone B derivative CTG12 in preparation of NLRP3 inflammasome inhibitors, and belongs to the technical field of biological medicine.The application provides the glycyrrhizin chalcone B derivative CTG12 in preparation of NLRP3 inflammasome inhibitors, and application in preparation of drugs for preventing or treating diseases related to abnormal activation of NLRP3 inflammasome; the compound CTG12 synthesized in the application has significant inhibition on caspase-1 activity generated by BMDM cells, the effect is about eight times higher than that of glycyrrhizin chalcone B, and the compound CTG12 has broad-spectrum and specific inhibition effect, and can effectively inhibit activation of NLRP3 inflammasome.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Preparation method of E-3,4-dihydroxyphenylvinyl ketone and application thereof as nerve protection drug

    CN103936577A

  • Pyridinedione carboxamide inhibitors of endothelial lipase

    US20140235673A1

  • Diarylalkanoids having activity as lipoxygenase inhibitors

    US4959503A